Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novartis Ag ADR
(NY:
NVS
)
102.57
-0.12 (-0.12%)
Official Closing Price
Updated: 7:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novartis Ag ADR
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
Alphabet Reports Q4 Results, Joins AMD, Tesla And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
January 31, 2024
U.S. stock futures were mostly lower this morning, with the Nasdaq futures falling more than 200 points on Wednesday.
Via
Benzinga
3 Hidden Healthcare Stocks Poised for a Breakout This Year
January 30, 2024
As the market preferences start to switch toward stable and defensive names like healthcare, these stocks could help your portfolio.
Via
InvestorPlace
AbbVie Stock Moves With Rising Relative Strength, Still Room To Grow
January 24, 2024
AbbVie shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Via
Investor's Business Daily
Gilead's Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of "Risks Of Secondary Cancer'
January 24, 2024
FDA issues classwide black box warning for CAR-T therapies due to T-cell cancer risk. Drops Gilead's cell therapy from the list.
Via
Benzinga
Exposures
Product Safety
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment
January 23, 2024
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.
Via
Benzinga
Exposures
Product Safety
(NVS) - Analyzing Novartis's Short Interest
January 05, 2024
Via
Benzinga
Big Players' Recent Trades in NVS Options
January 04, 2024
Via
Benzinga
Earnings Scheduled For January 31, 2024
January 31, 2024
Companies Reporting Before The Bell • Novartis (NYSE:NVS) is likely to report quarterly earnings at $1.68 per share on revenue of $11.56 billion.
Via
Benzinga
Earnings Outlook For Novartis
January 30, 2024
Via
Benzinga
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
January 29, 2024
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
January 13, 2024
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will...
Via
Talk Markets
Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst
January 12, 2024
Novartis halts pursuit of Cytokinetics acquisition, impacting promising heart drug. Analysts estimate $3.6 billion sales for Cytokinetics' cardiomyopathy drug by 2032. Still lead drug aficamten viewed...
Via
Benzinga
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
January 12, 2024
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut.
Via
Investor's Business Daily
Topics
ETFs
Novartis Retreats From Cytokinetics Deal, Dashing Hopes For Multi-Billion Dollar Acquisition
January 11, 2024
Novartis AG (NYSE: NVS) has decided to step back from pursuing the Cytokinetics Inc (NASDAQ: CYTK) acquisition, dealing a blow to the potential deal with the
Via
Benzinga
Bullish Continuation In '24? 3 Market Areas To Watch
January 10, 2024
This article discusses 3 market areas that should outperform dramatically over the next 12 months...
Via
Talk Markets
What's Been Happening With Cytokinetics Stock?
January 09, 2024
Cytokinetics, Incorporated (NASDAQ: CYTK) shares are trading lower on Tuesday, pulling back from Monday strength.
Via
Benzinga
Why Is Heart Failure Drug-Focused Cytokinetic Stock Trading Higher Today?
January 08, 2024
Cytokinetics Inc (NASDAQ: CYTK) shares are trading higher after a report on potential takeover talks with Novartis AG (NYSE: NVS).
Via
Benzinga
Cytokinetics Rockets 14% As Novartis Reportedly Nears A Buyout Deal
January 08, 2024
The company is working on a treatment for a disease that can lead to heart failure.
Via
Investor's Business Daily
Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today?
January 08, 2024
Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an
Via
Benzinga
J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value
January 08, 2024
The year's biggest medical conference kicked off with a melee of buyout news.
Via
Investor's Business Daily
Google's AI Spin-Off Isomorphic Labs Strikes Big Pharma Deals, Paving the Way for Future of Drug Discovery
January 08, 2024
Isomorphic Labs, a London-based spin-out of Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) Google's AI R&D division DeepMind, has announced strategic part
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Alphabet's Isomorphic Labs In Drug Discovery Deals With Eli Lilly, Novartis
January 07, 2024
Isomorphic Labs will get upfront cash and milestone payments.
Via
Investor's Business Daily
Week In Review: 2024 Kicks Off With Three Deals Worth A Total Of $4 Billion
January 07, 2024
Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Additionally, Allorion Therapeutics has out-licensed global rights (ex-China)...
Via
Talk Markets
Voyager Therapeutics Stock Tanked After-Hours - Here's Why
January 04, 2024
Voyager Therapeutics, Inc. (NASDAQ: VYGR) shares are trading lower in Thursday's after-hours session after announcing a proposed public offering
Via
Benzinga
VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today
January 02, 2024
VYGR stock is in focus as analysts expect more pharma deals in 2024, although some think these deals will be sunk by the Biden administration.
Via
InvestorPlace
Why Is Gene Therapy Focused Voyager Therapeutics Stock Soaring Today?
January 02, 2024
Voyager Therapeutics Inc (NASDAQ: VYGR) announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS), to advance pot
Via
Benzinga
Novartis Sweetens Its Deal With Voyager, And Voyager Stock — Up 25% — Flashes A Bullish Sign
January 02, 2024
The company inked an expanded collaboration deal with Novartis to test out gene therapies.
Via
Investor's Business Daily
Why Is Neurology Focused Cingulate Stock Trading Higher Today?
December 28, 2023
On Tuesday, Cingulate Inc (NASDAQ: CING) received FDA guidance f
Via
Benzinga
Why Is Cytokinetics (CYTK) Stock Up 70% Today?
December 27, 2023
With Cytokinetics hitting a homerun with its heart failure drug, CYTK stock skyrocketed in part due to takeover interest.
Via
InvestorPlace
Bristol Myers Squibb Takes On Novartis, Eli Lilly With RayzeBio $4B Deal In Radiopharmaceuticals
December 26, 2023
Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire RayzeBio Inc (NASDAQ: RYZB) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of <
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.